Brief: Theravance Biopharma Announces Approval Of Yupelri By China's NMPA
26/06/2025 11:03
June 26 (Reuters) - Theravance Biopharma Inc TBPH.O: THERAVANCE BIOPHARMA ANNOUNCES APPROVAL OF YUPELRI® (REVEFENACIN) BY CHINA'S NMPA THERAVANCE BIOPHARMA INC - APPROVAL TRIGGERS $7.5 MILLION MILESTONE PAYMENT FROM VIATRIS Source text: ID:nPn4vc42Wa Further company coverage: TBPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsTheravance Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates
Brief: Theravance Biopharma Q2 Operating Income USD -8.277 Million
Press Digest: Canada - June 30
Deals of the day-Mergers and acquisitions